NOVARTIS has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure and diabetes suggesting that Entresto (sacubitril/valsartan) tablets improved glycemic control, as assessed by hemoglobin A1c (HbA1c) testing, compared to angiotensin converting enzyme (ACE)-inhibitor enalapril.
"These results show that in addition to its compelling cardiovascular efficacy, Entresto may have important metabolic benefits for HFrEF patients with diabetes," said Vasant Narasimhan, global head of drug development and chief medical officer, Novartis.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Mar 17